Evidence map›Paper›PMID 30261620›Full record

ReviewCancers2018

The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.

Ibrahim Ragab Eissa, Itzel Bustos-Villalobos, Toru Ichinose, Shigeru Matsumura, Yoshinori Naoe, Noriyuki Miyajima, Daishi Morimoto, Nobuaki Mukoyama, Wu Zhiwen, Maki Tanaka and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Clinical immunotherapy in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ibrahim Ragab EissaCancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. brahimessa@med.nagoya-u.ac.jp.ORCID 0000-0001-9454-6327
Itzel Bustos-VillalobosCancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. bustositzel@med.nagoya-u.ac.jp.
Toru IchinoseCancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. t-ichinose@med.nagoya-u.ac.jp.
Shigeru MatsumuraCancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. smatsumu@med.nagoya-u.ac.jp.
Yoshinori NaoeCancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. ynaoe@med.nagoya-u.ac.jp.
Noriyuki MiyajimaDepartment of Transplantation and Endocrine Surgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. miyajima@med.nagoya-u.ac.jp.
Daishi MorimotoDepartment of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. d-morimoto@med.nagoya-u.ac.jp.
Nobuaki MukoyamaDepartment of Otolaryngology Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. tamgpad7042@gmail.com.
Wu ZhiwenCancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. wu.zhiwen@med.nagoya-u.ac.jp.
Maki TanakaTakara Bio Inc., Kusatsu, Shiga 525-0028, Japan. tanakamy@takara-bio.co.jp.
Hitoki HasegawaOffice of International Affairs, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. hitoki@med.nagoya-u.ac.jp.
Seiji SumigamaOffice of International Affairs, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. sumigama@med.nagoya-u.ac.jp.ORCID 0000-0001-6913-3731
Branko AleksicOffice of International Affairs, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. branko@med.nagoya-u.ac.jp.
Yasuhiro KoderaDepartment of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. ykodera@med.nagoya-u.ac.jp.
Hideki KasuyaCancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. kasuya@med.nagoya-u.ac.jp.

Funding

This work was supported by a 2016 Grant-in-Aid for challenging Exploratory Research 479 (16K15611) 16K15611
6 · The paper itself

Abstract

Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene laherparepvec (T-VEC, Imlygic

Indexed as

breast cancer clinical trialsclinical trialsgliomamelanomaoncolytic virusespancreatic

Identifiers

PMID30261620
PMCPMC6210336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.